BUZZ-IntelliPharmaceuticals International: Research action

Fri Sep 5, 2014 10:51am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drugmaker's U.S.-listed shares up 16 pct at $3.15

** Maxim Group analysts upgrade stock to "buy" and raised price target to $7 from $3

** "Based on our estimates of the numerous phase I trials now underway, we believe we could see Rexista (pain-killer drug) expedited in the marketplace much faster than we previously expected," analyst wrote in a note

** Up to Thursday's close, stock has fallen 27 percent this year